This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Persistent viruses === Using quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS) a maximum of five DNA viruses per individual have been identified. Included were several herpesviruses, hepatitis B virus, Merkel cell polyomavirus, and human papillomavirus 31. Given the reactivation and/or oncogenic potential of these viruses, their repercussion on hematopoietic and malignant disorders calls for further studies.
== Further reading == Luna C, Estévez M (January 2019). "Formation of allysine in β-lactoglobulin and myofibrillar proteins by glyoxal and methylglyoxal: Impact on water-holding capacity and in vitro digestibility". Food Chemistry. 271: 87–93. doi:10.1016/j.foodchem.2018.07.167. PMID 30236745. S2CID 52309183. Luna C, Arjona A, Dueñas C, Estevez M (March 2021). "Allysine and α-Aminoadipic Acid as Markers of the Glyco-Oxidative Damage to Human Serum Albumin under Pathological Glucose Concentrations". Antioxidants. 10 (3): 474. doi:10.3390/antiox10030474. PMC 8002732. PMID 33802856.
=== Recurring === Eme Ikwuakor as Elijah, an attorney at Jacobson Moore who was in a romantic relationship with Olympia Beau Bridges as Howard "Senior" Markston, a managing partner at Jacobson Moore, father of Julian, and soon-to-be ex-father-in-law of Olympia. He guardedly supports Olympia's career and efforts to develop a new revenue stream for the firm, telling her how he believes being father-in-law is a forever role. Patricia Belcher as Mrs. B, an administrative manager at Jacobson Moore. It is later revealed her full name is Emmalyn Belvin. Yael Grobglas as Shae Banfield, a jury consultant at Jacobson Moore Piper Curda as Kira, a woman who works at the information technology (IT) department at Jacobson Moore who begins a relationship with Sarah Marnee Carpenter as Ellie Kingston, Matty and Edwin's deceased daughter and Alfie's mother, who appears in flashbacks Andrea Londo as Simone, a recently hired junior associate at Jacobson Moore who attended the same law school as Sarah Niko Nicotera as Joseph "Joey" Danza, Alfie's father who is a drug addict Justina Machado as Eva (season 2), Senior's fourth ex-wife who is also a lawyer and member of the executive committee at Jacobson Moore James Lesure as Lester "The Wolf" Logan (season 2) Justin Cornwell as Mr. Hodges (season 2), Olympia's love interest who is also a lawyer Sarah Wright Olsen as Gwen (season 2), a productivity consultant evaluating Jacobson Moore Henry Haber as Hunter (season 2), an eager new associate on Olympia's team
Sources: en.wikipedia.org
Constitutionally, the Soviet Union was a federation. In accordance with provisions present in its Constitution (versions adopted in 1924, 1936 and 1977), each republic retained the right to secede from the USSR. Throughout the Cold War, this right was widely considered to be meaningless; however, the corresponding Article 72 of the 1977 Constitution was used in December 1991 to effectively dissolve the Soviet Union, when Russia, Ukraine, and Belarus seceded from the Union. Although the Union was created under an initial ideological appearance of forming a supranational union, it never de facto functioned as one; an example of the ambiguity is that the Ukrainian Soviet Socialist Republic in the 1930s officially had its own foreign minister, but that office did not exercise any true sovereignty apart from that of the union. The Constitution of the Soviet Union in its various iterations defined the union as a federation with the right of the republics to secede. This constitutional status led to the possibility of the parade of sovereignties once the republic with de facto (albeit not de jure) dominance over the other republics, the Russian one, developed a prevailing political notion asserting that it would be better off if it seceded. The de facto dominance of the Russian republic is the reason that various historians (for example, Dmitri Volkogonov and others) have asserted that the union was a unitary state in fact albeit not in law.
== Research == Mark Crislip, a practicing infectious disease specialist, examined the claims that bee venom can treat arthritis. He was unable to "find a clean, i.e., a non-TCPM based, randomized, placebo-controlled study of bee venom in humans for the treatment [of] arthritis." Bee venom is also considered ineffective for the treatment or prevention of cancer, with no clinical studies to date supporting such effects. According to the American Cancer Society, there is no scientific evidence that apitherapy or bee venom therapy can treat or change the course of cancer or any other disease. Clinical trials have shown that apitherapy is ineffective in treating multiple sclerosis or any other disease, and can exacerbate multiple sclerosis symptoms.
The Bergmann degradation is a series of chemical reactions designed to remove a single amino acid from the carboxylic acid (C-terminal) end of a peptide. First demonstrated by Max Bergmann in 1934, it is a rarely used method for sequencing peptides. The later developed Edman degradation is an improvement upon the Bergmann degradation, instead cleaving the N-terminal amino acid of peptides to produce a hydantoin containing the desired amino acid. The Bergmann degradation follows the earlier work of Bergmann and his close colleague Leonidas Zervas, combining the organic azide degradation of the Curtius rearrangement with the Bergmann-Zervas carbobenzoxy method, which they designed to occur under relatively mild conditions so as to allow peptide sequencing. A single round of the Bergmann degradation yields an aldehyde containing the sought after amino acid residue and the remaining fragment of the original peptide in amide form.
Sources: en.wikipedia.org
Larsson, Torbjörn; Bäck, Henry (2008). Governing and Governance in Sweden. Lund: Studentlitteratur AB. ISBN 978-91-44-03682-3. Petersson, Olof (2010). Den offentliga makten (in Swedish). Stockholm: SNS Förlag. ISBN 978-91-86203-66-5.
(2) The study of Raymond Damadian (New York Downstate Medical Center, 1971-1972): Inspired by Hazlewood and Chang's findings about cellular water relaxation time changes during muscle development, Damadian proposed that T1 is generally longer in tumors compared to normal tissues. He demonstrated this idea with a quick NMR measurement on rat tissues. Damadian also filed a patent in late 1972 for a full-body machine of using NMR to detect cancer. (3) The study of Paul Lauterbur (The State University of New York at Stony Brook, 1973): Lauterbur proposed to use a magnetic field gradient to conduct a 2-dimensional NMR scan. He called his method zeugmatography. For demonstration, he used CW NMR (not spin-echo) to image the proton spin density in an artificial sample consisting of two tubes of water. In the late 1970s, physicists Peter Mansfield at the University of Nottingham and Lauterbur developed MRI-related techniques, like the echo-planar imaging (EPI) technique. Raymond Damadian's work into nuclear magnetic resonance (NMR) has been incorporated into MRI, having built one of the first scanners. Advances in semiconductor technology were crucial to the development of practical MRI, which requires a large amount of computational power. This was made possible by the rapidly increasing number of transistors on a single integrated circuit chip. Mansfield and Lauterbur were awarded the 2003 Nobel Prize in Physiology or Medicine for their "discoveries concerning magnetic resonance imaging".
Amyloid beta (Aβ, Abeta or beta-amyloid) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid-beta precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ in a cholesterol-dependent process and substrate presentation. Both neurons and oligodendrocytes produce and release Aβ in the brain, contributing to formation of amyloid plaques. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold. A study has suggested that APP and its amyloid potential is of ancient origins, dating as far back as early deuterostomes.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.